NCT02234778Unknown不适用
Evaluation of the Use of the Tissue Genesis® Icellator Cell Isolation System™ for Autologous Adipose-Derived Stromal Vascular Fraction Cells to Treat Critical Limb Ischemia
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 20
- 试验地点
- 2
- 主要终点
- Amputation-Free Survival
研究概览
简要总结
The purpose of this study is to determine the safety and effectiveness of the Tissue Genesis® Icellator Cell Isolation System™ in Critical Limb Ischemia. The Icellator System™ device removes certain cells from the adipose (fat) tissue which will be used to treat patients with blockages in the arteries of their lower legs that may require a future amputation, which is caused by severe peripheral artery disease (PAD). The purpose of this study is to determine if treatment with cells that have been removed from the Icellator System™ device will reduce the number of major amputations and deaths in a six month time period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Critical limb ischemia (CLI), defined as ischemic pain at rest (Rutherford Category 4) or minor tissue loss of the limb (Rutherford Category 5), and with either toe artery occlusive pressure < 50 mmHg or TBI ≤ 0.5 or ankle artery occlusion pressure ≤ 60 mm Hg or ABI ≤ 0.5
- •No reasonable open or endovascular surgical options as determined by treating vascular specialist
- •Competent to give consent
- •Age 21 years or greater
- •Females of child bearing potential agree to use acceptable methods of contraception for the duration of the trial. Sexually active males agree to use an accepted and effective method of contraception for the duration of the trial.
- •All diabetic subjects will undergo baseline and 12-month follow-up retinal examinations conducted by a specialist
- •No current malignancy or history of previous malignancy within the last five years, with the exception of adequately treated non-melanoma cutaneous carcinoma (basal cell or squamous cell carcinoma of the skin).
排除标准
- •Major tissue loss of the index limb (Rutherford Category 6)
- •Limb revascularization surgery within 45 days of enrollment in this study
- •Subjects with less than 15% body fat as measured by calipers or electrical impedance
- •Subjects with less than a 2 cm x 2 cm roll of subcutaneous abdominal fat, when pinched between the examiner's fingers, while the subject is in a supine position
- •Poorly controlled diabetes mellitus evidenced by HbA1C > 10%. Diabetic subjects must have evidence of a glycosylated hemoglobin test (HbA1C) performed within the last 30 days.
- •Uncompensated congestive heart failure (New York Heart Association Class IV) and/or other conditions that preclude general anesthesia.
- •Myocardial infarction or stroke within the last 90 days.
- •Elevated liver function tests (AST or ALT more than twice the upper limit of normal).
- •Hematologic abnormalities.
- •Disease of the central nervous system and/or other conditions that impair cognitive function.
- •History of two or more episodes of pulmonary embolus with a documented deep venous thrombosis (DVT) (Duplex US or venography) in the index extremity or history of DVT in the index extremity without evidence of clot resolution (Duplex US or venography)
- •Infection of the index leg
- •Pregnant or lactating females. Prior to enrollment, women of child-bearing potential must have a negative urine pregnancy test.
- •Lower extremity venous disease or lymphedema with pitting edema in the index leg
- •Osteomyelitis in the index leg
- •Existing HIV diagnosis
- •Known terminal disease process with a life expectancy of less than one year
- •Subjects, in the investigator's opinion, requiring amputation within 30 days
- •Uncorrected stenosis(es) of greater than 50% in the common and/or external iliac artery and/or common femoral artery of the index leg
- •Presence of any clinical condition that in the opinion of the PI or the sponsor makes the patient not suitable to participate in the trial
结局指标
主要结局
Amputation-Free Survival
时间窗: 26 weeks
To obtain preliminary feasibility evidence of the ability of the Tissue Genesis Inc. (TGI) stromal vascular fraction (SVF) material to result in freedom from major amputation (above the ankle) or death at 26 weeks following treatment. Treatment failure is defined as the composite of major amputation of the treatment limb or all-cause death.
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
撤回
1 期
Stromal Vascular Fraction for Treatment of XerostomiaXerostomia Due to Radiotherapy (Disorder)NCT03061110Midwestern Regional Medical Center
Unknown
不适用
Evaluation of the Tissue Genesis Icellator Cell Isolation System to Treat Erectile DysfunctionErectile DysfunctionNCT03518333Tissue Genesis60
撤回
2 期
Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn ScarsRestrictive Burn Scars of Joint AreaNCT00620737Castle Creek Biosciences, LLC.
Unknown
1 期
Allogeneic ADSCs and Platelet-Poor Plasma Fibrin Hydrogel to Treat the Patients With Burn Wounds (ADSCs-BWs)Second- or Third-degree BurnsNCT03113747A.A. Partners, LLC20
已完成
2 期
Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary InsufficiencyInterdental Papillary InsufficiencyNCT00655889Castle Creek Biosciences, LLC.13